Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel applications of medicament Fingolimod

A drug and pharmacy technology, applied in the field of drug fingolimod, can solve problems such as being unknown, achieve remarkable effects, save resources, and shorten the research and development cycle

Inactive Publication Date: 2016-06-15
SHANDONG UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Combined with the existing technology, this article can only obtain the protective effect of fingolimod on MN9D cells treated with TNF-α. Whether fingolimod has an effect on Parkinson's patients and whether it can delay the pathological process of PD is currently unknown. No report, no way of knowing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel applications of medicament Fingolimod
  • Novel applications of medicament Fingolimod
  • Novel applications of medicament Fingolimod

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] The present invention will be further described below in conjunction with the accompanying drawings and embodiments.

[0027] Experimental materials: human neuroblastoma cell line SH-SY5Y was purchased from ATCC in the United States; C57BL / 6 mice were purchased from the Experimental Animal Center of Shandong University, all male, 8-10 weeks old; fingolimod was purchased from Caymanchemical Company; 6-OHDA was purchased from Sigma; p-AKT, AKT, p-ERK, and ERK antibodies were purchased from Cellsignalingtechnology; BDNF antibodies were purchased from Santacruz; TH antibodies were purchased from Chemicon; LDH and TUNEL kits were purchased from Roche, Annexin-V - FITC was purchased from BD.

[0028] experimental method:

[0029] 1. Use SH-SY5Y neuroblastoma cell culture cell line. Use DMEM-F12 medium with 10% fetal bovine serum. Incubator conditions: 37°C, 5% CO 2 . Change medium once a day. Passage every other day.

[0030] 2. Determination of cell viability by MTT m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses new applications of a medicament Fingolimod. The applications comprise applications of Fingolimod or pharmaceutically acceptable salts, esters, and solvates thereof to preparation of a medicament for protecting a dopaminergic nerve cell strain SH-SY5Y damaged by 6-OHDA, and applications of Fingolimod or pharmaceutically acceptable salts, esters, and solvates thereof to prevention and / or treatment of a neurodegenerative disease, wherein the neurodegenerative disease is Parkinson's disease. Researches show that Fingolimod can delay progression of the Parkinson's disease with substantial effects; mechanisms of action of Fingolimod which is used as a novel medicament derived from natural products are different from mechanisms of action of clinical existed medicaments for resisting Parkinson's disease, and mainly have special emphasis on protection effects of dopaminergic neurons, so that a cross resistance phenomenon does not happen.

Description

technical field [0001] The invention relates to a new application of the drug fingolimod. Background technique [0002] Parkinson's disease (PD) is a common neurodegenerative disease among middle-aged and elderly people. With the improvement of people's living standards and the aggravation of population aging, the incidence of neurodegenerative diseases represented by PD is increasing year by year. It is the leading cause of death after cardiovascular diseases and malignant tumors, and it imposes a heavy burden on patients and society. The pathogenesis of PD is complex, and there is no effective treatment at present. Commonly used clinical drugs such as levodopa can only improve symptoms, but cannot delay the disease process. After 3-5 years of application, its curative effect will gradually decline and cause serious side effects such as "on-off" phenomenon. Therefore, it is urgent to find drugs that can delay the disease. Effective therapeutic drugs for the process. [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61P25/28A61P25/16
CPCA61K31/137
Inventor 娄海燕魏欣冰任曼茹韩民兴
Owner SHANDONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com